Pharming Group Nv · EURONEXT:PHARM
Pharming Group Nv — Investor Day (October 2019)
84 slides from Pharming Group Nv's investor day presentation, Oct 26, 2019
Slide 1: Pharming
eee ty Pharming
Slide 2: Pharming Forum Day 26 October 2019
Pharming Group Sijmen de Vries Chief Executive Officer Bruno Giannetti Robin Wright Chief Medical Officer Chief Financial Officer Mireille Sanders Anurag Relan Senior Vice President, Operations Vice President, Clinical Research/Medical Affairs Pharming Forum Day 26 October 2019
Slide 3: Safe Harbour Statement
Safe Harbour Statement The information contained in this document and communicated verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published, in whole or in part, for any purp
Slide 4: Company Overview
Company Overview Public Company: Euronext: PHARM: ~€750million (~$820 million) Domiciled: the Netherlands, ~206 employees globally Current Focus: Rare and Ultra-rare disease development and commercialization • Marketed product: RUCONEST® • Recombinant human C1-esterase inhibitor (enzyme replacement
Slide 5: Pharming today and into the future
Pharming today and into the future “End to End” infrastructure High Potential Pipeline Pharming has all the capabilities needed for sustainable, high Solid, growth profitable revenue Today, we are a profitable, growing and fully integrated, from generation platform to commercialization, multiple pro
Slide 6: Solid, profitable revenue generation
Solid, profitable revenue generation
Slide 7: RUCONEST: Strong Execution of Commercial Strategy
RUCONEST® : Strong Execution of Commercial Strategy HAE is a complex, serious disease with many US - RUCONEST® Net Sales (€ millions) idiosyncrasies and a varied market. The current approved therapies all address certain specific 134,3 segments/phenotypes of HAE. RUCONEST® as the only recombinant PR
Slide 8: RUCONEST: Patient Segmentation
RUCONEST®: Patient Segmentation Convenience Market (Prophylactic therapies) Breakthrough Convenience is not as important Attacks for this group; it’s all about efficacy and reliability # of HAE patients RUCONEST® Segment Estimated to be Pharming expands use with LCM and other ~20-30% of messaging (C
Slide 9: High Potential Pipeline
4% Pharming ai rnin: High Potential Pipeline
Slide 10: Investment Strategy: Focus, Leverage our Strengths
Investment Strategy: Focus, Leverage our Strengths Continued Investment in HAE Investment in new indications for rhC1INH such as Pre-eclampsia and AKI for C1INH Licensing/acquisition of additional rare/ultra-rare asset near-to-market Active Business Development aimed at capital efficient and smart i
Slide 11: High Potential Pipeline
High Potential Pipeline Approval & Lead Commercialization Optimization Preclinical Phase I Phase II Phase III RUCONEST® Acute Hereditary Angioedema (HAE) RUCONEST® Life Cycle RUCONEST® HAE Prophylaxis (ID) RUCONEST® HAE Acute (IM) rhC1 INH Franchise rhC1 INH Pre-Eclampsia All development plans have
Slide 12: From Milk to Medicine
From Milk to Medicine Mireille Sanders MSc Sr VP Operations 12
Slide 13: From Milk to Medicine
From Milk to Medicine Downstream Fill & Milking & Processing Finish Skimming/ (DSP) (F&F) Upstream processing (USP) Packaging Production & Labeling Transport Storage
Slide 14: Step 1: USP
Step 1: USP • 4x per week milking • Skimming of milk • Shelf-life 4 years
Slide 15: Step 2 and 3: Transport and Storage
Step 2 and 3: Transport and Storage • Transport of freezers • Controlled storage at ≤ -60 °C
Slide 16: Step 5: Downstream Processing
Step 5: Downstream Processing Step 1 Step 2 Step 3 Step 4 Step 5 milk Step 6 Step 7 Step 8 Step 9 Goal: • Purification DS DS Freezing • Virus inactivation/removal • Concentration 2 bags • Formulation ~90 bags Drug Substance (DS)
Slide 17: Step 5: Downstream Processing
Step 5: Downstream Processing
Slide 18: Step 6: Transport
Step 6: Transport 4% Pharming
Slide 19: Step 7: Fill & Finish
Step 7: Fill & Finish DS DS Step 1 Step 2 Step 3 DS DS Step 4 Step 5 4 bags ~2500 vials
Slide 20: Step 7: Fill & Finish
Step 7: Fill & Finish 4% Pharming
Slide 21: Step 9: Packaging & Labeling
Neen Step 9: Packaging & Labeling 4% Pharming For intravenous use. nevi et Ean retiey Route erent crise Excipients: Sucrose, drat (E331), Care ood (E500). Mecicinal product subject 0 mogieal preter. eas te Sewers Chater ht Inaba ariege yn 150 E ure PHARMING Aes 150 U ———
Slide 22: From Milk to Medicine
From Milk to Medicine USP DSP F/F Milk batch Day milk pool 1 bag skimmed milk Pooled DS ≈ 10 treatments Poolen melk en DSP Skimming Fill & Finish Milk bag Drug Substance batch Drug Product batch
Slide 23: RUCONEST in Hereditary Angioedema
RUCONEST® in Hereditary Angioedema Prof. Bruno Giannetti MD PhD 23
Slide 24: Overview of HAE
Overview of HAE Genetic and Biochemical Background Clinical Picture HAE RUCONEST® (C1 esterase inhibitor [recombinant]) Recombinant Technology Clinical Data Latest Developments 24
Slide 25: The Complement Cascade - Contact Pathway
The Complement Cascade - Contact Pathway TRIGGER Trace FXIIa or trace activity in native FXII prekallikrein HMW kininogen surface FXII FXIIa HMW kininogen kallikrein HMW kininogen bradykinin FXII FXIIa surface B1 receptor B2 receptor = Inhibited by RUCONEST ANGIOEDEMA RUCONEST is a recombinant C1-IN
Slide 26: The Complement Cascade - Overview
The Complement Cascade - Overview Tissue injury Proteases Proteases inhibited: inhibited: • FXIIa • C1r, C1s activation • Kallikrein • MASPs INHIBITION OF Complement INFLAMMATORY Contact PROTEASES System Pathway C1INH Inflammatory anaphylatoxins bradykinin peptides Inflammation 26
Slide 27: HAE – A C1INH Deficiency
HAE – A C1INH Deficiency HAE With Normal TYPE I TYPE II C1-INH • Characterized by low levels (below • Associated with normal or • Previously known as type III HAE 50% of normal) and elevated antigenic levels low inhibitory function of C1-INH of C1-INH with low • Most cases are due to unknown functio
Slide 28: HAE Attacks Vary in Frequency, Severity and Localization
HAE Attacks Vary in Frequency, Severity and Localization 50 Frequency of Attacks Among Patients With HAE1 Reporting HAE Attacks Percentage of Patients 40 Type I/Type II HAE (n=106) 30 HAE with Normal C1-INH (n=37) 20 10 0 2-3 Times Onceaa week Week 2-3 Times Once Lessevery Than Once 2 - 3 times a We
Slide 29: HAE Attacks – Clinical Examples
HAE Attacks – Clinical Examples Facial swelling Hand swelling Abdominal swelling during an HAE attack during an HAE attack during an HAE attack Swelling can start in one area and spread to another. Sometimes, this can become life-threatening. It's important to treat all HAE swells at the first sign
Slide 30: Selected Data on Treatment of Acute HAE Attacks
SELECTED DATA ON TREATMENT OF ACUTE HAE ATTACKS 30
Slide 31: RUCONEST Provided Rapid Symptom Relief from Acute Attacks
RUCONEST Provided Rapid Symptom Relief from Acute Attacks Start to symptom relief in Studies 2 and 31 Riedl MA, et al. Ann Allergy Asthma Immunol. 2014;112(2):163-169.e1. 31
Slide 32: One Dose of RUCONEST Stopped Most Acute Attacks
One Dose of RUCONEST Stopped Most Acute Attacks 97 % of attacks needed JUST ONE DOSE of RUCONEST 50 U/kg (open-label extension phase, n=44 [170 attacks]) ~9 out of 10 patients achieved symptom relief in the pivotal clinical trial with just one dose (n=44) 32
Slide 33: One Dose of RUCONEST Stopped Most Acute Attacks
One Dose of RUCONEST Stopped Most Acute Attacks Patients enrolled in clinical studies were required to be experiencing a moderate to severe HAE attack prior to starting RUCONEST TIME OF 1 HOUR 4 HOURS 24 HOURS taking RUCONEST after taking RUCONEST after taking RUCONEST after taking RUCONEST 33
Slide 34: Additional Dosing Requirements
Additional Dosing Requirements • 79% of HAE attacks were treated with 1 dose of therapy • Icatibant had the highest number of treated attacks requiring >1 dose (44%) Need of Retreatment 100 HAE Attacks (%) 80 60 40 20 0 pdC1-INH Cinryze Icatibant rhC1-INH 1 Treatment >1 Treatment HAE = hereditary an
Slide 35: RUCONEST: The First and Only Plasma-free C1-INH
RUCONEST: The First and Only Plasma-free C1-INH 97% of acute attacks were successfully treated with just one dose Relief that lasted for at least three days High dose of C1-INH to treat the root cause of HAE Symptom relief that’s proven rapid and reliable Recombinant design with a dependable supply
Slide 36: Selected Data on Prophylaxis of Acute HAE Attacks
SELECTED DATA ON PROPHYLAXIS OF ACUTE HAE ATTACKS 36
Slide 37: Prophylaxis For HAE Phase 2: Study Design
Prophylaxis For HAE Phase 2: Study Design Double-blind, multicenter, crossover study Patient population: • ≥13 years of age • Functional C1-INH <50% of normal using a chromogenic assay • Frequent HAE attacks* Randomly assigned to 1 of 6 treatment sequences, each consisting of 3 separate 4-week treat
Slide 38: Clinical Response Frequency (PP Population)
8 Clinical Response Frequency (PP Population) • Achievement of clinical response* more consistent with twice-weekly dosing of rhC1-INH Twice-Weekly Dosing (n=23) Once-Weekly Dosing (n=23) 50% threshold 50% threshold 7 7 71.2% reduction (weighted‐ 6 6 average) in attacks for 13 6 6 Number of Patients
Slide 39: Plasma-Derived C1-INH Prophylaxis: Clinical Response
9 Plasma-Derived C1-INH Prophylaxis: Clinical Response • Prophylaxis with plasma-derived C1-INH (n=22) resulted in varying reductions in HAE attack frequency 5 5 50% threshold Patients (n) 4 3 3 3 2 2 2 2 2 1 1 1 1 0 0 < 0* 0–9 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80–89 90–100 Reduction in HAE
Slide 40: Possible Mode of Action of rhC1-INH in HAE Prophylaxis
Possible Mode of Action of rhC1-INH in HAE Prophylaxis Normalize C1-INH levels for irreversible binding to target Immunohistochemical localization of rhC1-INH and proteases (factor XII, kallikrein)1-3 pdC1-INH in mouse cortex after focal ischemia and 30 minutes of reperfusion4 Differences in glycosy
Slide 41: Special Cases/Recent Results
SPECIAL CASES/RECENT RESULTS 41
Slide 42: Is IM Administration of rhC1-INH an Alternative for Acute Attacks?
Is IM Administration of rhC1-INH an Alternative for the Treatment of Acute Attacks in Patients With HAE? Staevska M, Valerieva A. AAAAI/WAO Joint Congress. March 2-5, 2018; Orlando, FL AAAAI = American Academy of Allergy, Asthma & Immunology; HAE = hereditary angioedema; IM = intramuscular; rhC1-INH
Slide 43: IM rhC1-INH Self-Administration
IM rhC1-INH Self-Administration • 1 to 2 vials of rhC1-INH; each vial • 5 patients with difficult venous access, reconstituted in 10 mL of water for injection difficulties accessing medical facilities, or • Injected into musculus gluteus maximus or unnecessary treatment delay musculus quadriceps fem
Slide 44: Delay in Treatment and HAE Attack Duration
Delay in Treatment and HAE Attack Duration • The time to IM rhC1-INH treatment was shorter versus time to IV rhC1-INH treatment • Mean delay in treatment was shorter with IM administration for all 5 patients • IM-treated HAE attacks had shorter mean duration in 4 of 5 patients Mean Delay in Treatmen
Slide 45: Comparison of Pain With IM Versus IV Administration
Comparison of Pain With IM Versus IV Administration rhC1-INH Administration Non–rhC1-INH Mean Pain Score Comparable IM VAS Patient IV IM Injection* 0 1 2 3 4 5 6 7 8 9 10 1 1.4 1.6 1.5 2 0.5 0.6 0.5 No pain Mild, Nagging, Distressing, Intense, Worst possible, 3 1.2 1.7 1.5 annoying uncomfortable, mi
Slide 46: Long-Term Prophylaxis With rhC1-INH: Is IM an Option?
Long-Term Prophylaxis With rhC1-INH in Patients With HAE: Is IM Administration an Option? Valerieva A, Krusheva B, Staevska M. AAAAI/WAO Joint Congress. March 2-5, 2018; Orlando, FL AAAAI = American Academy of Allergy, Asthma & Immunology; HAE = hereditary angioedema; IM = intramuscular; rhC1-INH =
Slide 47: IM Administration of rhC1-INH
IM Administration of rhC1-INH • 2 vials rhC1-INH 2100 IU; each vial reconstituted • 2 patients with difficult venous access and 4 to 7 HAE in 10 mL of water for injection • 1 vial injected into musculus gluteus maximus; attacks/month before prophylaxis was introduced had 1 vial injected into musculu
Slide 48: Efficacy of IM rhC1-INH Prophylaxis
Efficacy of IM rhC1-INH Prophylaxis • 1 breakthrough HAE attack occurred － Abdominal/urogenital attack in Patient 1 after stressful event; successfully treated with IM rhC1- INH 4200 IU administered 20 minutes after onset of attack • Five events prodromal symptoms reported rhC1-INH Administration No
Slide 49: rhC1-INH for Short-Term Prophylaxis in Patients With HAE
rhC1-INH for Short-Term Prophylaxis in Patients With HAE* Zanichelli A, Staevska M, Jesenak, M, et al. ACAAI Annual Scientific Meeting. November 15-19, 2018; Seattle, WA *Valerieva A, et al. J Allergy Clin Immunol Pract. Published online ahead of print August 19, 2019. doi: 10.1016/j.jaip.2019.08.01
Slide 50: Patient Population
Patient Population • Retrospective analysis of rhC1-INH Patients administration before medical procedures or Parameter (N=51) stressful life events Age, y, median (range) 44 (17-73) － Control cases included patients who weren’t Female, n (%) 32 (62.7) receiving long-term prophylaxis and did not rece
Slide 51: Procedures, Dose, and Timing of Short-Term Prophylaxis
Procedures, Dose, and Timing of rhC1-INH Short-Term Prophylaxis Administration Cases, n (%) rhC1-INH Self-Control Prophylaxis Group* Median rhC1-INH dose: 3075 IU (range, 2100-4200 IU) Category (n=70) (n=26) Dental procedure† 37 (52.9) 17 (65.4) High-risk 36 (97.3) 16 (94.1) Low-risk 1 (2.7) 1 (5.9)
Slide 52: Efficacy Outcomes
Efficacy Outcomes 100 97,1 96,1 rhC1-INH prophylaxis (n=70 88,6 88,2 procedures) Attack Free Procedures (%) rhC1-INH prophylaxis (n=51 80 procedures with no LTP) Control: no prophylaxis (n=26 procedures)* 60 40 23,1 19,2 20 n=68 n=49 n=6 n=62 n=45 n=5 0 Within 2 Days Postprocedure Within 7 Days Post
Slide 53: rhC1-INH as Short-Term Prophylaxis for Dental Procedures
rhC1-INH as Short-Term Prophylaxis for Dental Procedures in Patients With Angioedema: A Case Series Valerieva A, Staevska M, Jesenak M, et al. Presented at AAAAI Annual Meeting. February 22-25, 2019; San Francisco, CA AAAAI = American Academy of Allergy Asthma & Immunology; rhC1-INH = recombinant hu
Slide 54: Patient Population
Patient Population • Retrospective analysis of rhC1-INH administration before Patients dental procedures in patients with C1-INH-HAE Parameter (N=29) • Control cases included patients who weren’t receiving 44 Age, y, median (range) long-term prophylaxis and did not receive short-term (17.5-73.1) pro
Slide 55: Efficacy Outcomes
Efficacy Outcomes • For 1 attack within 2 days post-procedure in rhC1-INH group － rhC1-INH (4200 IU; 37.5 IU/kg) was administered 230 minutes pre-procedure － Patient had mild knee edema and required no treatment *Self-control group in which patients did not receive long-term or short-term prophylaxi
Slide 56: Experience With rhC1-INH for HAE Attacks During Pregnancy
Experience With rhC1-INH for HAE Attacks During Pregnancy* Bernstein JA, Moldovan D, Hakl R, et al. ACAAI 2018 Annual Scientific Meeting. November 15-19, 2018; Seattle, WA *Moldovan D, et al. J Allergy Clin Immunol Pract. Published online ahead of print June 3, 2019. doi: https://doi.org/10.1016/j.j
Slide 57: Results
Results • Pregnant women with HAE who received rhC1-INH were followed to full term rhC1-INH Dose Number of Second rhC1-INH Dose Rescue Medication Patient Age, y Weight, kg Per Attacks Treatments Required for Any Attack Required for Any Attack Case 1 27 65.5 2100 IU 9 No No Case 2 NR 72.0 2100-4200 I
Slide 58: Results (Cont’d)
Results (Cont’d) • There were no AEs considered related to rhC1-INH treatment during pregnancy period － One patient (case 6) experienced an episode of nausea, vomiting, and diarrhea, considered related to a “stomach bug” • All pregnancies resulted in live births with no fetal distress, birth defects
Slide 59: Hereditary Angioedema Attack In Utero and Treatment of Mother and Fetus
Hereditary Angioedema Attack In Utero and Treatment of Mother and Fetus Vesna Grivcheva-Panovska, M.D., Ph.D., and Bruno Giannetti, M.D., Ph.D., Poster accepted for presentation, ACAAI, 2019 Annual Scientific Meeting (November 7-11, 2019; Houston, Texas). 59
Slide 60: Leveraging our “End to End” Infrastructure
Leveraging our “End to End” Infrastructure
Slide 61: Research and Development: Meeting the Unmet Need
Research and Development: Meeting the Unmet Need Prof. Bruno Giannetti MD PhD 61
Slide 62: rhC1-INH in Pre-Eclampsia
rhC1-INH in Pre-Eclampsia 62
Slide 63: Pre-eclampsia overview
• Overview of Pre-eclampsia (NL: zwangerschapsvergiftiging) The Complement Cascade PE - Definition, Prevalence PE - Clinical Manifestation Pathophysiological Hypotheses Clinical Plan 63
Slide 64: Therapeutic potential for rhC1INH
Therapeutic potential for rhC1INH • C1INH appears to slow inflammatory response and thus limit tissue damage – potentially applicable in a number of clinical conditions Potential effect of adding C1-INH Fatal Disease situation 3500 3500 Plasma Concentration 3000 3000 Fatal Level Fatal Level 2500 250
Slide 65: Other potential options for development of rhC1INH
Other potential options for development of rhC1INH • The complement and contact systems are known to play a role in many diseases with an immune component, such as: Acute Kidney Injury Not/ limited unmet needs: Asthma Pre-eclampsia Irritable Bowel Syndrome Cardiac Protection Glomerulonephritis Delay
Slide 66: Pre-eclampsia: Diagnosis
Pre-eclampsia: Diagnosis • A multisystem disorder • Usually first detected by hypertension • Proteinuria common but not essential for a clinical diagnosis of pre-eclampsia in the presence of other organ involvement, including feto-placental unit Criteria: De novo hypertension after 20 weeks and new
Slide 67: Pre-eclampsia (PE), Prevalence, Complications
Pre-eclampsia (PE), Prevalence, Complications • Pre-eclampsia (PE) has a prevalence of 1-17% throughout the world. Estimated yearly cases of PE in the US alone: 120.000+. (Steegers et al., 2010; Osungbade and Ige, 2011) • Delivery is presently the only therapy of PE, but this is not an option for ea
Slide 68: Pre-eclampsia (PE) Complications
Pre-eclampsia (PE) Complications G.Dekker, Presentation, NY, June 21, 2018 68
Slide 69: Pre-eclampsia (PE), Pathophysiological Hypotheses
Pre-eclampsia (PE), Pathophysiological Hypotheses • Pregnant women and pre- eclamptic women have reduced circulating C1INH levels. Severely affected patients have significantly reduced C1INH levels (W M Halbmeyer et al., 1991) • Postulated mechanisms to the aetiology of PE (immunological, infectious
Slide 70: The Complement Cascade - Overview
The Complement Cascade - Overview Tissue injury Proteases Proteases inhibited: inhibited: • FXIIa • C1r, C1s activation • Kallikrein • MASPs INHIBITION OF Complement INFLAMMATORY Contact PROTEASES System Pathway C1INH Inflammatory anaphylatoxins bradykinin peptides Inflammation 70
Slide 71: Complement cascade involvement in Pre-eclampsia
Complement cascade involvement in Pre-eclampsia JF Regal, S Fleming 2017 71
Slide 72: Pre-eclampsia (PE) Clinical Plan
Pre-eclampsia (PE) Clinical Plan • There is no animal model mimicking appropriately the human pre-eclampsia situation. • Ruconest® has been given to > 50 pregnant HAE patients to treat or to prevent HAE attacks (up to 40 times during a single pregnancy) – no safety issue detected (Pharming, PSUR 201
Slide 73: Research and Development: Activated PI3K-δ Syndrome (APDS)
Research and Development: Activated PI3K-δ Syndrome (APDS) Dr. Anurag Relan 73
Slide 74: Primary Immunodeficiency and APDS Background
Primary Immunodeficiency and APDS Background • Primary immunodeficiencies (PID) lead to immune system dysregulation with numerous resulting complications o Prevalence 1 in 1200 o More than 300 genes known to cause different PIDs o Highly variable clinical presentation, but increased susceptibility t
Slide 75: PI3Kδ and APDS Pathophysiology
PI3Kδ and APDS Pathophysiology • Phosphoinositide 3–kinase PI3K is a signaling pathway involved in a broad variety of cellular functions • The PI3K delta isoform is primarily present in the immune system • Regulation of PI3KD activity is required to ensure normal function and differentiation of PI3K
Slide 76: APDS Clinical Spectrum
APDS Clinical Spectrum Varying clinical manifestations of symptoms and signs • Recurrent infections • Organomegaly • Malignancy • Autoimmunity Jamee M, et al. Clin Rev Allergy Immunology. 2019. ADPS Patient Cohort Study, n=53 RTI/Pneumonia Bronchietasis Lymphadenopathy Splenomegaly Herpes viremia No
Slide 77: APDS Misdiagnosis
APDS Misdiagnosis Distribution of primary clinical diagnosis of APDS patients Review of 243 published APDS patients • Symptoms occurred early 1-2 years of age • Median age diagnosis: 12 years • Positive family history of PID: 39% Jamee M, et al. Clin Rev Allergy Immunology. 2019. 77
Slide 78: APDS Treatment Options
APDS Treatment Options • Current treatment options for APDS: o Symptomatic treatment e.g., antibiotics o Immune globulin replacement therapy (IVIG/SCIG) o Stem cell transplantation Leniolisib o Case reports of mTOR inhibitor rapamycin • Leniolisib o Potent, selective PI3Kδ inhibitor o Treats the roo
Slide 79: Clinical: Leniolisib - Pivotal Study Program
Clinical: Leniolisib - Pivotal Study Program Two part core study and extension study PoC Part 1 (6 patients) Within-patient dose E1 (42 patients) finding N=6 Long-term safety & • intra-subject dose finding efficacy • Endpoints: PK and PD Part 2 (30 patients) N=42 • Open-label Confirmation of • Safet
Slide 80: Leniolisib - Key Results from Part of Core Study
Leniolisib - Key Results from Part 1 of Core Study Reduction in spleen size Patient Spleen volume ∆baseline Lymph node ∆baseline 1 -26% -51% 2 -39% -13% 3 -57% -65% 4 -36% -33% 5 -39% -48% 6 -37% -31% Mean -39% -40% Lymph node size Rao VK, et al. Blood. 2017. 80
Slide 81: Financial Performance & 2019 Outlook
Financial Performance & 2019 Outlook
Slide 82: Third Quarter 2019: Financial Results
Third Quarter 2019: Financial Results 9 months to 30 September 2019 2019 2018 % Amounts in €m except per share 3rd Quarter 1st 9 months 1st 9 months Change data Income Statement Revenue from product sales 45.3 122.8 97.7 26% Other revenue 0.2 0.6 0.6 Total revenue 45.5 123.4 98.3 26% Gross profit 40
Slide 83: Summary and Outlook 2019 and beyond
Summary and Outlook 2019 and beyond “End to End” infrastructure High Potential Continued growth of RUCONEST® sales Pipeline Continued profitability and positive cash flows Continued investments in expansion of manufacturing Solid, profitable Expedite development of Leniolisib to FDA and EMA approval
Slide 84: www.pharming.com
www.pharming.com ENXTAM: PHARM Bloomberg: PHAR.AS